ACUR Share Price

Open 0.94 Change Price %
High 1.19 1 Day 0.08 8.70
Low 0.92 1 Week 0.11 12.36
Close 1.00 1 Month -0.02 -1.96
Volume 1038920 1 Year -1.01 -50.25
52 Week High 3.52
52 Week Low 0.85
ACUR Important Levels
Resistance 2 1.25
Resistance 1 1.15
Pivot 1.04
Support 1 0.85
Support 2 0.75
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR)

ACUR Technical Analysis 5
As on 9th Dec 2016 ACUR Share Price closed @ 1.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.93 & Strong Sell for SHORT-TERM with Stoploss of 1.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACUR Target for December
1st Target up-side 1.06
2nd Target up-side 1.16
3rd Target up-side 1.26
1st Target down-side 0.78
2nd Target down-side 0.68
3rd Target down-side 0.58
ACUR Other Details
Segment EQ
Market Capital 66501960.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.acurapharm.com
ACUR Address
ACUR
616 N. North Court
Suite 120
Palatine, IL 60067
United States
Phone: 847-705-7709
Fax: 847-705-5399
Interactive Technical Analysis Chart Acura Pharmaceuticals, Inc. ( ACUR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Acura Pharmaceuticals, Inc.
ACUR Business Profile
Acura Pharmaceuticals, Inc. incorporated on April 10, 1935, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Impede Technology is a combination of inactive ingredients that prevent the extraction of pseudo-ephedrine from tablets and disrupt the direct conversion of pseudo-ephedrine from tablets into methamphetamine. As of December 31. 2012, the Company had seven additional opioid products utilizing Aversion in various stages of development. The Company’s product, Oxecta is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta utilizes its Aversion Technology. The Company’s Aversion Technology Opioid products in development include Hydrocodone bitartrate/acetaminophen, Hydromorphone HCl, Methadone HCl, Morphine Sulfate, Oxycodone HCl/acetaminophen, Oxymorphone HCl and Tramadol HCl. On January 23, 2012, Oxecta was made commercially available by Pfizer Inc. (Pfizer).